pipobroman has been researched along with Erythremia in 43 studies
Pipobroman: An antineoplastic agent that acts by alkylation.
pipobroman : An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The overall impact of hydroxyurea (HU) or pipobroman treatments on the long-term outcome of patients with polycythemia vera (PV) has not been assessed in randomized studies." | 9.15 | Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. ( Chevret, S; Chomienne, C; Dosquet, C; Kiladjian, JJ; Rain, JD, 2011) |
| "From 1968 to 1993, 179 newly diagnosed patients with polycythemia vera (PV) were enrolled in a prospective study using pipobroman as first chemotherapy." | 9.10 | Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. ( Bernard, JF; Bruno, F; Gardin, C; Kiladjian, JJ; Renoux, M, 2003) |
| "Nonradiomimetic drugs, hydroxyurea (HU) and pipobroman (Pi), were administred to relatively young subjects with polycythemia vera (PV) in an attempt to decrease the leukemogenic risk observed in patients treated with 32P." | 9.08 | Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. ( Najean, Y; Rain, JD, 1997) |
| "Between 1980 and 1991, 96 patients with documented polycythemia vera were treated by hydroxyurea or pipobroman, according to a protocol including randomization, and maintenance therapy." | 9.07 | [Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies]. ( Najean, Y, 1992) |
| "A trial was conducted between 1970 and 1981 with pipobroman (PB) in 100 consecutive patients with polycythemia vera (PV), followed for a median time of 60 months, to evaluate the efficacy of this drug and assess the risk of acute leukemia." | 9.05 | Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia. ( Bernasconi, C; Brusamolino, E; Canevari, A; Salvaneschi, L, 1984) |
| "Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications." | 8.90 | Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. ( Newberry, KJ; Sever, M; Verstovsek, S, 2014) |
| "We report here a very unusual patient with Polycythemia vera treated with Pipobroman who developed severe aplastic anemia following administration of the drug." | 7.70 | Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera. ( Bouscary, D; Casadevall, N; Dreyfus, F; Fontenay-Roupie, M; Jondeau, K; Quarre, MC; Vassilief, D; Viguié, F; Zompi, S, 1999) |
| "Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120)." | 7.67 | Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients. ( Bernasconi, C; Brusamolino, E; Canevari, A; Merante, S; Salvaneschi, L, 1984) |
| "Between 1971 and 1981, 74 patients with polycythemia vera were treated with pipobroman using a high-dose induction, low-dose maintenance regimen." | 7.66 | Pipobroman therapy of polycythemia vera. ( Duhamel, G; Gorin, NC; Najman, A; Parlier, Y; Stachowiak, J, 1982) |
| "Pipobroman (PB) is a neutral amide of piperazine with a chemical structure close to that of alkylating agents, although the exact mechanism of action of PB has not been demonstrated." | 6.42 | Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. ( Lazzarino, M; Passamonti, F, 2003) |
| "An analysis of the risk of progression towards leukemia, carcinoma and myelofibrosis was performed in 93 patients treated by 32P alone (PVSG protocols) since 1970-1979, 395 patients over the age of 65 years treated by 32P with or without maintenance therapy using hydroxyurea (French protocol) since 1980-1994, and 202 patients under the age of 65 treated by either hydroxyurea or pipobroman since 1980." | 6.18 | Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". ( Dresch, C; Echard, M; Goguel, A; Grange, MJ; Lejeune, F; Najean, Y; Rain, JD, 1996) |
| " All patients received PB at the dosage of 1 mg/kg/day until response was achieved (hematocrit value <50% in males and <45% in females)." | 5.30 | Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). ( Avvisati, G; Cosenza, M; Latagliata, R; Malagnino, F; Montefusco, E; Petti, MC; Spadea, A; Spadea, T, 1998) |
| "The overall impact of hydroxyurea (HU) or pipobroman treatments on the long-term outcome of patients with polycythemia vera (PV) has not been assessed in randomized studies." | 5.15 | Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. ( Chevret, S; Chomienne, C; Dosquet, C; Kiladjian, JJ; Rain, JD, 2011) |
| "From 1968 to 1993, 179 newly diagnosed patients with polycythemia vera (PV) were enrolled in a prospective study using pipobroman as first chemotherapy." | 5.10 | Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. ( Bernard, JF; Bruno, F; Gardin, C; Kiladjian, JJ; Renoux, M, 2003) |
| "Nonradiomimetic drugs, hydroxyurea (HU) and pipobroman (Pi), were administred to relatively young subjects with polycythemia vera (PV) in an attempt to decrease the leukemogenic risk observed in patients treated with 32P." | 5.08 | Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. ( Najean, Y; Rain, JD, 1997) |
| "To compare by a prospective study in low risk polycythemia vera (PV) patients alone two drugs: hydroxyurea and pipobroman." | 5.08 | [Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age]. ( Brahimi, S; Echard, M; Fermand, JP; Gruyer, P; Lejeune, F; Najean, Y; Rain, JD, 1998) |
| "Between 1980 and 1991, 96 patients with documented polycythemia vera were treated by hydroxyurea or pipobroman, according to a protocol including randomization, and maintenance therapy." | 5.07 | [Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies]. ( Najean, Y, 1992) |
| "A trial was conducted between 1970 and 1981 with pipobroman (PB) in 100 consecutive patients with polycythemia vera (PV), followed for a median time of 60 months, to evaluate the efficacy of this drug and assess the risk of acute leukemia." | 5.05 | Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia. ( Bernasconi, C; Brusamolino, E; Canevari, A; Salvaneschi, L, 1984) |
| "Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications." | 4.90 | Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. ( Newberry, KJ; Sever, M; Verstovsek, S, 2014) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "A 57-year-old male who had suffered from polycythemia vera (PV) and had been treated with pipobroman, carbazilquinon and busulfan for ten years presented with fever." | 4.78 | [Megakaryoblastic transformation associated with disseminated intravascular coagulation in the course of polycythemia vera: a case report]. ( Hino, K; Koike, T; Sakashita, A; Sato, S; Tomoyasu, S; Tsuruoka, N, 1992) |
| "We report here a very unusual patient with Polycythemia vera treated with Pipobroman who developed severe aplastic anemia following administration of the drug." | 3.70 | Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera. ( Bouscary, D; Casadevall, N; Dreyfus, F; Fontenay-Roupie, M; Jondeau, K; Quarre, MC; Vassilief, D; Viguié, F; Zompi, S, 1999) |
| "Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120)." | 3.67 | Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients. ( Bernasconi, C; Brusamolino, E; Canevari, A; Merante, S; Salvaneschi, L, 1984) |
| "Between 1971 and 1981, 74 patients with polycythemia vera were treated with pipobroman using a high-dose induction, low-dose maintenance regimen." | 3.66 | Pipobroman therapy of polycythemia vera. ( Duhamel, G; Gorin, NC; Najman, A; Parlier, Y; Stachowiak, J, 1982) |
| " Anaemia was the most common adverse event in patients receiving ruxolitinib (rates per 100 patient-years of exposure were 8·9 for ruxolitinib and 8·8 for the crossover population), though most anaemia events were mild to moderate in severity (grade 1 or 2 anaemia rates per 100 patient-years of exposure were 8·0 for ruxolitinib and 8·2 for the crossover population)." | 2.94 | Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. ( Besses, C; Blau, IW; Dong, T; Durrant, S; Francillard, N; Griesshammer, M; Harrison, CN; Hino, M; Kiladjian, JJ; Kirito, K; Masszi, T; Mesa, R; Miller, CB; Moiraghi, B; Pane, F; Passamonti, F; Rosti, V; Rumi, E; Vannucchi, AM; Verstovsek, S; Wroclawska, M; Zachee, P, 2020) |
| "Pipobroman (PB) is a neutral amide of piperazine with a chemical structure close to that of alkylating agents, although the exact mechanism of action of PB has not been demonstrated." | 2.42 | Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. ( Lazzarino, M; Passamonti, F, 2003) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration." | 1.51 | Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. ( Alvarez-Larran, A; Angona, A; Barbui, T; Beggiato, E; Benevolo, G; Bertolotti, L; Betti, S; Bonifacio, M; Cacciola, R; Carli, G; Carobbio, A; Casetti, IC; Cattaneo, D; De Stefano, V; Delaini, F; Di Veroli, A; Elli, EM; Erez, D; Finazzi, G; Fox, ML; Ghirardi, A; Gomez, M; Griesshammer, M; Guglielmelli, P; Iurlo, A; Lunghi, F; Marchetti, M; Masciulli, A; McMullin, MF; Palandri, F; Palova, M; Patriarca, A; Perez-Encinas, M; Recasens, V; Rumi, E; Scaffidi, L; Stephenson, C; Tieghi, A; Vannucchi, AM; Vianelli, N; Wille, K, 2019) |
| " All patients received PB at the dosage of 1 mg/kg/day until response was achieved (hematocrit value <50% in males and <45% in females)." | 1.30 | Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). ( Avvisati, G; Cosenza, M; Latagliata, R; Malagnino, F; Montefusco, E; Petti, MC; Spadea, A; Spadea, T, 1998) |
| " Relapses occurred in 30% of the cases but responded to pipobroman at the initial high dosage level." | 1.26 | [Management of polycythaemia with pipobroman]. ( Duhamel, G; Gorin, NC; Najman, A; Parlier, Y; Perreau-Boutet, MC; Stachowiak, J, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (27.91) | 18.7374 |
| 1990's | 16 (37.21) | 18.2507 |
| 2000's | 8 (18.60) | 29.6817 |
| 2010's | 6 (13.95) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kiladjian, JJ | 4 |
| Zachee, P | 1 |
| Hino, M | 1 |
| Pane, F | 1 |
| Masszi, T | 1 |
| Harrison, CN | 1 |
| Mesa, R | 1 |
| Miller, CB | 1 |
| Passamonti, F | 3 |
| Durrant, S | 1 |
| Griesshammer, M | 2 |
| Kirito, K | 1 |
| Besses, C | 1 |
| Moiraghi, B | 1 |
| Rumi, E | 2 |
| Rosti, V | 1 |
| Blau, IW | 1 |
| Francillard, N | 1 |
| Dong, T | 1 |
| Wroclawska, M | 1 |
| Vannucchi, AM | 2 |
| Verstovsek, S | 2 |
| Tefferi, A | 3 |
| Barbui, T | 2 |
| Andriani, A | 1 |
| Elli, E | 1 |
| Trapè, G | 1 |
| Villivà, N | 1 |
| Fianchi, L | 1 |
| Di Veroli, A | 2 |
| Niscola, P | 1 |
| Centra, A | 1 |
| Anaclerico, B | 1 |
| Montanaro, G | 1 |
| Martini, V | 1 |
| Aroldi, A | 1 |
| Carmosino, I | 1 |
| Voso, MT | 1 |
| Breccia, M | 1 |
| Montanaro, M | 1 |
| Foà, R | 1 |
| Latagliata, R | 2 |
| Ghirardi, A | 1 |
| Masciulli, A | 1 |
| Carobbio, A | 1 |
| Palandri, F | 1 |
| Vianelli, N | 1 |
| De Stefano, V | 1 |
| Betti, S | 1 |
| Iurlo, A | 1 |
| Cattaneo, D | 1 |
| Delaini, F | 1 |
| Bonifacio, M | 1 |
| Scaffidi, L | 1 |
| Patriarca, A | 1 |
| Casetti, IC | 1 |
| Stephenson, C | 1 |
| Guglielmelli, P | 1 |
| Elli, EM | 1 |
| Palova, M | 1 |
| Bertolotti, L | 1 |
| Erez, D | 1 |
| Gomez, M | 1 |
| Wille, K | 1 |
| Perez-Encinas, M | 1 |
| Lunghi, F | 1 |
| Angona, A | 1 |
| Fox, ML | 1 |
| Beggiato, E | 1 |
| Benevolo, G | 1 |
| Carli, G | 1 |
| Cacciola, R | 1 |
| McMullin, MF | 2 |
| Tieghi, A | 1 |
| Recasens, V | 1 |
| Marchetti, M | 1 |
| Alvarez-Larran, A | 1 |
| Finazzi, G | 1 |
| Sever, M | 1 |
| Newberry, KJ | 1 |
| Stein, BL | 1 |
| Moliterno, AR | 1 |
| Tiu, RV | 1 |
| Chevret, S | 1 |
| Dosquet, C | 1 |
| Chomienne, C | 2 |
| Rain, JD | 8 |
| Gardin, C | 1 |
| Renoux, M | 1 |
| Bruno, F | 1 |
| Bernard, JF | 2 |
| Lazzarino, M | 2 |
| Briere, J | 1 |
| Fenaux, P | 1 |
| Brusamolino, E | 3 |
| Salvaneschi, L | 2 |
| Canevari, A | 3 |
| Bernasconi, C | 3 |
| Merante, S | 2 |
| Najman, A | 2 |
| Stachowiak, J | 2 |
| Parlier, Y | 2 |
| Gorin, NC | 2 |
| Duhamel, G | 2 |
| Perreau-Boutet, MC | 1 |
| Paitel, JF | 1 |
| Trechot, P | 1 |
| Stockemer, V | 1 |
| Dorvaux, V | 1 |
| Lederlin, P | 1 |
| Boivin, P | 2 |
| Najean, Y | 5 |
| Dresch, C | 2 |
| Goguel, A | 1 |
| Lejeune, F | 2 |
| Echard, M | 2 |
| Grange, MJ | 1 |
| Sánchez Fayos, J | 1 |
| Román Barbero, A | 1 |
| Nevado Reviriego, I | 1 |
| Petti, MC | 1 |
| Spadea, A | 1 |
| Avvisati, G | 1 |
| Spadea, T | 1 |
| Montefusco, E | 1 |
| Cosenza, M | 1 |
| Malagnino, F | 1 |
| Pearson, TC | 1 |
| Green, AR | 1 |
| Reilly, JT | 1 |
| Harrisoni, G | 1 |
| Heis, N | 1 |
| Rintelen, C | 1 |
| Gisslinger, B | 1 |
| Knöbl, P | 1 |
| Lechner, K | 1 |
| Gisslinger, H | 1 |
| Bauters, F | 2 |
| Bouscary, D | 1 |
| Jondeau, K | 1 |
| Viguié, F | 1 |
| Zompi, S | 1 |
| Fontenay-Roupie, M | 1 |
| Quarre, MC | 1 |
| Vassilief, D | 1 |
| Dreyfus, F | 1 |
| Casadevall, N | 1 |
| Silverstein, MN | 1 |
| Baraté, C | 1 |
| Klersy, C | 1 |
| Orlandi, E | 1 |
| Castelli, G | 1 |
| Lengfelder, E | 1 |
| Hehlmann, R | 1 |
| Fermand, JP | 1 |
| Gruyer, P | 1 |
| Brahimi, S | 1 |
| Jouet, JP | 1 |
| Goudemand, M | 1 |
| Hino, K | 1 |
| Sato, S | 1 |
| Sakashita, A | 1 |
| Tomoyasu, S | 1 |
| Tsuruoka, N | 1 |
| Koike, T | 1 |
| Jamshidi, K | 1 |
| Ansari, A | 1 |
| Windschitl, HE | 1 |
| Swaim, WR | 1 |
| Miyazaki, T | 1 |
| Ishizaki, T | 1 |
| Maekawa, I | 1 |
| Sano, H | 1 |
| Idaka, K | 1 |
| Bignotti, G | 1 |
| Visca, U | 1 |
| Confalonieri, C | 1 |
| Bilski-Pasquier, G | 1 |
| Blanc, CM | 1 |
| Bousser, J | 1 |
| Böhnel, J | 1 |
| Stacher, A | 1 |
| Vallée, G | 1 |
| Dormont, J | 1 |
| Soulier, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)[NCT01243944] | Phase 3 | 222 participants (Actual) | Interventional | 2010-10-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Durable Primary Response was defined as any participant who achieved the primary outcome measure and who maintained their response up to 48 weeks after randomization. (NCT01243944)
Timeframe: 48 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Ruxolitinib | 20.0 |
| Best Available Therapy | 0.9 |
Primary response was defined as having achieved hematocrit control (the absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32) and Spleen Volume Reduction (a greater than or equal to 35% reduction from baseline in spleen volume at Week 32). (NCT01243944)
Timeframe: 32 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Ruxolitinib | 22.7 |
| Best Available Therapy | 0.9 |
Complete Hematological Remission at Week 32 was defined as any participant who achieved hematocrit control with a platelet count less than or equal to 400 X 10^9/L and a white blood cell count less than or equal to 10 X 10^9/L. (NCT01243944)
Timeframe: 32 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Ruxolitinib | 23.6 |
| Best Available Therapy | 8.0 |
Durable Complete Hematological Remission was defined as any participant who achieved Complete Hematological Remission at Week 32 and maintained their response up to 48 weeks after randomization. (NCT01243944)
Timeframe: 48 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Ruxolitinib | 20.9 |
| Best Available Therapy | 0.9 |
Durable Hematocrit Control was defined as any participant who achieved phlebotomy eligibility independence from Week 8 to Week 32 and maintained hematocrit control up to 48 weeks after randomization. (NCT01243944)
Timeframe: 48 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Ruxolitinib | 54.5 |
| Best Available Therapy | 1.8 |
Durable Spleen Volume Reduction was defined as a participant who achieved at least 35% reduction from baseline in spleen volume at Week 32 and maintained that response 48 weeks after randomization. (NCT01243944)
Timeframe: 48 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Ruxolitinib | 37.3 |
| Best Available Therapy | 0.9 |
Duration of spleen volume reduction is defined as the time from the first occurrence of a >=35% reduction from baseline in spleen volume until the date of the first documented progression. (NCT01243944)
Timeframe: 256 Weeks
| Intervention | probability (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 weeks | 32 weeks | 48 weeks | 64 weeks | 80 weeks | 96 weeks | 112 weeks | 128 weeks | 144 weeks | 160 weeks | 176 weeks | 192 weeks | 208 weeks | 224 weeks | 240 weeks | 256 weeks | |
| Ruxolitinib | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.98 | 0.95 | 0.95 | 0.95 | 0.93 | 0.93 | 0.93 | 0.87 | 0.72 | NA | NA |
Duration of the absence of phlebotomy eligibility is defined as the time from the first occurrence of absence of phlebotomy eligibility until the date of the first documented progression. (NCT01243944)
Timeframe: 256 Weeks
| Intervention | probability (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 weeks | 32 weeks | 48 weeks | 64 weeks | 80 weeks | 96 weeks | 112 weeks | 128 weeks | 144 weeks | 160 weeks | 176 weeks | 192 weeks | 208 weeks | 224 weeks | 240 weeks | 256 weeks | |
| Ruxolitinib | 1.00 | 1.00 | 0.97 | 0.92 | 0.91 | 0.91 | 0.87 | 0.84 | 0.84 | 0.82 | 0.79 | 0.77 | 0.73 | 0.73 | 0.73 | 0.73 |
Duration of the overall clinicohematologic response was defined as the time from the first occurrence of complete response (CR) or partial response (PR) until the date of the first documented disease progression. (NCT01243944)
Timeframe: 256 Weeks
| Intervention | probability (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 weeks | 32 weeks | 48 weeks | 64 weeks | 80 weeks | 96 weeks | 112 weeks | 128 weeks | 144 weeks | 160 weeks | 176 weeks | 192 weeks | 208 weeks | 224 weeks | 240 weeks | 256 weeks | |
| Ruxolitinib | 1.00 | 0.99 | 0.96 | 0.91 | 0.88 | 0.88 | 0.85 | 0.82 | 0.82 | 0.80 | 0.75 | 0.70 | 0.67 | 0.67 | 0.67 | 0.67 |
"Duration of the complete hematological remission is defined as the time from the first occurrence of complete hematological remission until the date of the first documented progression (end of response).~Kaplan-Meier estimates are provided for duration of complete hematological remission." (NCT01243944)
Timeframe: Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study
| Intervention | probability (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 weeks | 32 weeks | 48 weeks | 64 weeks | 80 weeks | 96 weeks | 112 weeks | 128 weeks | 144 weeks | 160 weeks | 176 weeks | 192 weeks | 208 weeks | 224 weeks | 240 weeks | 256 weeks | |
| Ruxolitinib | 1.00 | 1.00 | 0.88 | 0.83 | 0.74 | 0.74 | 0.69 | 0.69 | 0.65 | 0.65 | 0.55 | 0.55 | 0.55 | 0.55 | NA | NA |
"Duration of the primary response is defined as the time from the first occurrence when both components of the primary endpoint are met until the date of the first documented disease progression (end of response).~Kaplan-Meier estimates are provided for duration of primary response." (NCT01243944)
Timeframe: Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study
| Intervention | probability (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 weeks | 32 weeks | 48 weeks | 64 weeks | 80 weeks | 96 weeks | 112 weeks | 128 weeks | 144 weeks | 160 weeks | 176 weeks | 192 weeks | 208 weeks | 224 weeks | 240 weeks | 256 weeks | |
| Ruxolitinib | 1.00 | 1.00 | 0.92 | 0.92 | 0.92 | 0.88 | 0.84 | 0.84 | 0.84 | 0.79 | 0.79 | 0.74 | 0.74 | 0.74 | NA | NA |
Durable Complete or Partial Clinicohematologic Response was defined as any participant who achieved complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera at Week 32 and maintained that response 48 weeks after randomization. (NCT01243944)
Timeframe: 48 Weeks
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response rate | Partial response rate | |
| Best Available Therapy | 0.9 | 0.9 |
| Ruxolitinib | 7.3 | 50.9 |
Overall Clinicohematologic Response is defined as any participant who achieved a complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera (PV). A Complete Response (CR) is defined as: hematocrit control, spleen volume reduction at least 35% from baseline, platelet count less than or equal to 400 x 10(9)/L, and white blood cell count less than or equal to 10 x 10(9)/L. A Partial Response (PR) is defined as hematocrit control or response in all 3 of the other criteria. (NCT01243944)
Timeframe: 32 Weeks
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response rate | Partial response rate | |
| Best Available Therapy | 0.9 | 18.8 |
| Ruxolitinib | 8.2 | 54.5 |
12 reviews available for pipobroman and Erythremia
| Article | Year |
|---|---|
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
Topics: Antineoplastic Agents; Busulfan; Disease Management; Drug Resistance; Histone Deacetylase Inhibitors | 2014 |
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost of Illness; Disease Progression | 2014 |
[Polycythemia vera].
Topics: Aged; Diagnosis, Differential; Erythrocyte Count; Female; Hematocrit; Humans; Hydroxyurea; Male; Mid | 2002 |
Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Topics: Abortion, Spontaneous; Acute Disease; Alkylating Agents; Female; Humans; Leukemia, Myeloid; Middle A | 2003 |
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Topics: Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interfero | 2006 |
A review of the therapeutic agents used in the management of polycythaemia vera.
Topics: Hematocrit; Humans; Hydroxyurea; Interferons; Pipobroman; Polycythemia Vera; Randomized Controlled T | 2007 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
[Efficacious treatment of a fatal blood disease: polycythemia vera].
Topics: Acute Disease; Alkylating Agents; Busulfan; Chlorambucil; Humans; Hydroxyurea; Leukemia, Myeloid; Le | 1997 |
[Vaquez disease. Diagnosis, course, treatment].
Topics: Aged; Antineoplastic Agents, Alkylating; Antisickling Agents; Diagnosis, Differential; Female; Human | 1998 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
[Polycythemia vera: current status of therapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bloodletting; Clinical Trials | 2000 |
[Megakaryoblastic transformation associated with disseminated intravascular coagulation in the course of polycythemia vera: a case report].
Topics: Blast Crisis; Busulfan; Carbazilquinone; Disseminated Intravascular Coagulation; Humans; Leukemia, M | 1992 |
10 trials available for pipobroman and Erythremia
| Article | Year |
|---|---|
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Drug Therapy, Combination; Fibrino | 2020 |
Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Follow-Up Studies; Humans; Hydroxyurea; Male | 2011 |
Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cause of Deat | 2003 |
Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia.
Topics: Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Leukemia, Monocytic, Acute; Leukemia, M | 1984 |
Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
Topics: Acute Disease; Bloodletting; Combined Modality Therapy; Humans; Hydroxyurea; Leukemia; Phosphorus Ra | 1993 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.
Topics: Antineoplastic Agents; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; Middle Aged; Pipobroman | 1997 |
[Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age].
Topics: Adult; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; Middle Aged; Pip | 1998 |
[Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies].
Topics: Digestive System Diseases; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; Middle Aged; Pipobr | 1992 |
Intermediary analysis of a French protocol of treatment of polycythemias (1980-1990): 253 patients. The French Group for the Study of Polycythemias.
Topics: Clinical Protocols; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; | 1991 |
22 other studies available for pipobroman and Erythremia
| Article | Year |
|---|---|
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Female; Humans; Hydroxyurea; Leuke | 2019 |
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
Topics: Antineoplastic Agents; Case-Control Studies; Humans; Hydroxyurea; Neoplasms, Second Primary; Nitrile | 2019 |
Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients.
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Male; Middle Aged; Pipobroman; Polycythemia Vera; Pros | 1984 |
Pipobroman therapy of polycythemia vera.
Topics: Drug Evaluation; Female; Humans; Male; Pipobroman; Polycythemia Vera; Primary Myelofibrosis | 1982 |
[Management of polycythaemia with pipobroman].
Topics: Female; Humans; Leukemia; Male; Myeloproliferative Disorders; Pipobroman; Polycythemia; Polycythemia | 1982 |
[Acute liver disease during treatment with pipobroman and allopurinol].
Topics: Acute Disease; Allopurinol; Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Pipob | 1995 |
Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Female; Follow-Up | 1998 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
Leukemic transformation in polycythemia Vera. MPD(UK) Study Group.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leukemia; Pipobroman; Polycythemia Vera | 1998 |
The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera.
Topics: Adult; Aged; Aged, 80 and over; Busulfan; Drug Tolerance; Erysipelas; Erythropoiesis; Female; Hemato | 1999 |
Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera.
Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Cyclosporine; Humans; Immunosuppressive Agents; | 1999 |
Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Hum | 2000 |
[Hydroxyurea--is it a harmless drug in Vaquez disease?]].
Topics: Aged; Alopecia; Combined Modality Therapy; Cystitis; Erectile Dysfunction; Female; Fever; Follow-Up | 2001 |
[Little known treatment of primary polycythemia: pipobroman (apropos of 19 cases)].
Topics: Adult; Aged; Humans; Male; Middle Aged; Pipobroman; Polycythemia Vera | 1976 |
Primary thrombocythemia.
Topics: Adult; Aged; Blood Coagulation Tests; Bone Marrow Examination; Busulfan; Follow-Up Studies; Gastroin | 1973 |
[Clinical trial of pipobroman (N,N'-bis-(3-bromopropionyl) piperazine) in eight patients with polycythemia vera].
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Pipobroman; Polycythemia Vera | 1972 |
[Pipobroman in the treatment of some cases of polycythemia vera].
Topics: Adult; Aged; Antineoplastic Agents; Bromine; Female; Humans; Male; Middle Aged; Piperazines; Pipobro | 1971 |
Evaluation of two antineoplastic agents, PIPOBROMAN (vercyte) and thioguanine.
Topics: Antineoplastic Agents; Humans; Leukemia, Myeloid; Pipobroman; Polycythemia Vera; Thioguanine | 1967 |
[Treatment of Vaquez's polycythemia with 1-4, bis-3-bromopropionyl-piperazine. Study of 36 cases].
Topics: Aged; Antineoplastic Agents; Bromine; Erythrocyte Count; Female; Humans; Leukemia, Myeloid; Leukopen | 1968 |
[On the effect of a new cytostatic drug in chronic myeloses and polycythemias].
Topics: Animals; Antineoplastic Agents; Bromine; Chronic Disease; Erythrocyte Count; Erythropoiesis; Female; | 1968 |
[Present treatment of the Vaquez's disease].
Topics: Aged; Anemia; Anticoagulants; Antineoplastic Agents; Blood Donors; Blood Volume; Bloodletting; Busul | 1969 |